Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Assets Average (2016 - 2025)

Historic Assets Average for Spyre Therapeutics (SYRE) over the last 10 years, with Q3 2025 value amounting to $521.7 million.

  • Spyre Therapeutics' Assets Average rose 2173.23% to $521.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $521.7 million, marking a year-over-year increase of 2173.23%. This contributed to the annual value of $475.2 million for FY2024, which is 13010.56% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Assets Average of $521.7 million as of Q3 2025, which was up 2173.23% from $554.3 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Assets Average registered a high of $589.1 million during Q1 2025, and its lowest value of $61.8 million during Q1 2023.
  • For the 5-year period, Spyre Therapeutics' Assets Average averaged around $270.6 million, with its median value being $162.6 million (2021).
  • As far as peak fluctuations go, Spyre Therapeutics' Assets Average tumbled by 4062.82% in 2022, and later skyrocketed by 57110.12% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Assets Average stood at $119.5 million in 2021, then crashed by 31.92% to $81.4 million in 2022, then skyrocketed by 237.49% to $274.6 million in 2023, then soared by 87.49% to $514.8 million in 2024, then increased by 1.35% to $521.7 million in 2025.
  • Its last three reported values are $521.7 million in Q3 2025, $554.3 million for Q2 2025, and $589.1 million during Q1 2025.